The role of CBFbeta in AML1-ETO's activity.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

9 citing papers in PubMed.

1. Core Binding Factor Leukemia: Chromatin Remodeling Moves Towards Oncogenic Transcription.Cancers · 2019
   Review
2. New insights into transcriptional and leukemogenic mechanisms of AML1-ETO and E2A fusion proteins.Frontiers in biology · 2016
   Article
3. JMJD1C is required for the survival of acute myeloid leukemia by functioning as a coactivator for key transcription factors.Genes & development · 2015
   Article
4. ERG and FLI1 binding sites demarcate targets for aberrant epigenetic regulation by AML1-ETO in acute myeloid leukemia.Blood · 2012
   Article
5. Molecular pathogenesis of core binding factor leukemia: current knowledge and future prospects.International journal of hematology · 2011
   Review
6. RUNX1 mutations in clonal myeloid disorders: from conventional cytogenetics to next generation sequencing, a story 40 years in the making.Critical reviews in oncogenesis · 2011
   Review
7. Structure of the AML1-ETO NHR3-PKA(RIIα) complex and its contribution to AML1-ETO activity.Journal of molecular biology · 2010
   Article
8. RUNX1 repression-independent mechanisms of leukemogenesis by fusion genes CBFB-MYH11 and AML1-ETO (RUNX1-RUNX1T1).Journal of cellular biochemistry · 2010
   Article
9. Accelerated leukemogenesis by truncated CBF beta-SMMHC defective in high-affinity binding with RUNX1.Cancer cell · 2010
   Article

Corrections and comments

• Comment on
  CBFbeta is critical for AML1-ETO and TEL-AML1 activity.2009

Authors and funding

3 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as